Making Life-Saving Treatment Available to Patients on an Unlicensed Basis in Neglected or Overlooked Countries
Condition
Life-threatening genetic disorder
Drug Type
Approved
Where Approved
US and Europe
About the Advocacy Group
Congenital Hyperinsulinism International (CHI) was founded in 2005 by a group of concerned parents of children born with the condition. CHI partners with leading international HI physicians, researchers, and patient advocates to prevent brain damage and death, search for better treatments and improve the quality of life for all HI patients. CHI is the only US based nonprofit working globally to support patients born with the condition.
Challenge
WEP Clinical was contacted by a patient representative from CHI who was receiving requests from patients who wanted to gain access to an EMA and FDA approved product that was not commercially available in their countries. These patients had no other treatment options available and were at risk of experiencing worsening symptoms which could lead to emergency surgery. The advocacy group wanted to help these patients but did not know how to get the product into countries where it is not registered.
WEP Solution
The advocacy group partnered with WEP Clinical to benefit from our experience making product available to patients in neglected or hard to reach countries on an unlicensed basis. Our team was able to source the product from a local wholesaler at a low cost and hold it at our UK warehouse facility. We then worked directly with the patients and their physicians to understand and fulfill the requirements for unlicensed medicines import into their respective countries. Once all the paperwork was in place, our strategic partnerships with leading logistics companies allowed us to deliver the product to the patients’ countries, clear it through customs and transport it on to the treating physicians.
Testimonial from the patient’s grandfather:
